GENova issues clarifying press release

NEW YORK, Sept. 12 /PRNewswire-FirstCall/ -- GENova Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous press releases regarding the patents currently in GENova's IP portfolio.

GENova owns the rights to a range of drug targets and has filed patent application for all of them. The patents have not yet been approved and are therefore considered 'patents-pending'. It has been brought to GENova's attention that previous releases were not entirely clear on this issue and may have been misconstrued by some investors. Any statements made prior to this announcement which stated or implied that patents have been granted are incorrect and should not be relied upon in making investment decisions.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies.Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

GENova Biotherapeutics, Inc.

CONTACT: about Genova Biotherapeutics, Inc., please contact Investor
Relations: Windfall Communications LLC, Brian Cook, 1-866-797-8703,
info@windfallcommunications.com

Teamsters Call on Whole Foods, UNFI to Support Health Reform

OAKLAND, Calif., Sept. 12 /PRNewswire-USNewswire/ -- Today the Teamsters protested at the "Entrepreneur's Open Forum" at the Numi Tea Garden to highlight Whole Food's hypocrisy of claiming to support sustainable policies while its CEO lobbies against real health reform for its workers and customers. Executives from Whole Foods and its leading supplier United Natural Foods, Inc. led discussions on "strategies for healthy business growth."

The Whole Foods CEO, in a Wall Street Journal op-ed, attacked President Obama's efforts to reform America's ailing health care system. Whole Foods believes that Americans have no right to health care and that health care should be an individual responsibility. That's easy for its CEO, who can afford expensive private health insurance, to say.

The Teamsters believe it is shameful for Whole Foods to seek to shift the health care burden even further onto individuals and to call for less government help in solving America's health care crisis.

"Whole Foods' CEO is talking out of both sides of his mouth when it comes to enacting real change in health reform," said Teamsters General President James P. Hoffa. "We can't allow corporate agendas to stop us from making health care affordable for everyone."

The Teamsters call upon Whole Foods, and its principal supplier UNFI, to promote a sustainable organic food supply chain and sustainable jobs, and support our President's efforts for a sustainable health care system for America.

The International Brotherhood of Teamsters was founded in 1903 and represents 1.4 million hardworking men and women in the United States, Canada and Puerto Rico.

International Brotherhood of Teamsters

CONTACT: Galen Munroe of the International Brotherhood of Teamsters,
+1-202-624-6911, gmunroe@teamster.org

Web Site: http://www.teamster.org/

GeoEye, Inc. Commences Cash Tender Offer and Consent Solicitation for its Floating Rate Senior Secured Notes Due 2012

DULLES, Va., Sept. 11 /PRNewswire-FirstCall/ -- GeoEye, Inc. today announced that it has commenced a cash tender offer (the "Tender Offer") to purchase any and all of its outstanding $250.0 million aggregate principal amount of Floating Rate Senior Secured Notes due 2012 (the "Notes"). In conjunction with the Tender Offer, GeoEye is also soliciting consents (the "Consent Solicitation" and together with the Tender Offer, the "Offer") to adopt certain proposed amendments to the indenture under which the Notes were issued that would eliminate substantially all of the restrictive covenants and certain event of default provisions and modify certain other provisions. The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated Sept. 11, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080625/LAW528LOGO)

The Offer is scheduled to expire at midnight, New York City time, on Oct. 8, 2009, unless extended or earlier terminated (the "expiration date"). The total consideration for each $1,000 principal amount of Notes tendered and accepted for payment will be $1,070, which includes the consent payment of $30 per $1,000 principal amount of Notes. In order to receive the total consideration, holders of Notes must tender and not withdraw their Notes and deliver and not revoke their corresponding consents on or prior to the consent deadline, which is 5:00 p.m., New York City time, on Sept. 24, 2009, unless extended or earlier terminated. Holders of Notes who tender their Notes after the consent deadline and on or prior to the expiration date will only receive the tender offer consideration of $1,040 per $1,000 principal amount of Notes, which is the total consideration minus the consent payment. In addition to the total consideration or the tender offer consideration, as applicable, holders of Notes that are purchased in the Offer will receive accrued and unpaid interest from the most recent interest payment date on the Notes to, but not including, the applicable settlement date. Holders of approximately 64% of the outstanding principal amount of Notes have indicated that they intend to tender their Notes and deliver consents prior to the consent deadline.

Holders of Notes who desire to tender their Notes must consent to the proposed amendments and holders may not deliver consents to the proposed amendments without tendering their related Notes. A holder of Notes may not revoke its consent without withdrawing the Notes tendered pursuant to the Offer. Holders of Notes may withdraw their tenders and revoke their consents at any time at or prior to the consent deadline but not thereafter.

The Offer is conditioned upon the satisfaction of, or, where applicable, GeoEye's waiver of, certain conditions, including (a) the consummation of a financing on terms satisfactory to GeoEye and resulting in the receipt by GeoEye of proceeds in an amount sufficient finance the Offer and the redemption of any Notes that remain outstanding after the expiration of the Offer, (b) the tender of at least a majority in principal amount of the outstanding Notes at or prior to the consent deadline (thereby obtaining the requisite consents for the proposed amendments to the indenture governing the Notes), (c) the execution of the supplemental indenture implementing the proposed amendments to the indenture governing the Notes and (d) certain other conditions as described in the Offer to Purchase and Consent Solicitation Statement. If any of the conditions is not satisfied, GeoEye will not be obligated to accept for purchase, or to pay for, Notes tendered (and corresponding consents) and may delay the acceptance for payment of, any tendered Notes, in each event, subject to applicable laws, and may terminate, extend or amend the Offer and may postpone the acceptance for purchase of, and payment for, Notes so tendered.

The primary purpose of the Consent Solicitation and proposed amendments is to eliminate substantially all of the restrictive covenants and certain events of default and modify certain other provisions of the indenture under which the Notes were issued. GeoEye currently intends to redeem any Notes that remain outstanding after the expiration of the Offer and to exercise its rights under the indenture to satisfy and discharge the indenture governing the Notes. This press release does not constitute a notice of redemption under the optional redemption provision of the indenture governing the Notes.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Offer is being made solely pursuant to the Offer to Purchase and Consent Solicitation Statement and related transmittal documents.

Requests for documents may be directed to IPREO, the Information Agent, at (877) 746-3583 or (201) 499-3500.

J.P. Morgan Securities Inc. will act as Dealer Manager for the Tender Offer and Solicitation Agent for the Consent Solicitation. Questions regarding the Tender Offer and Consent Solicitation may be directed to J.P. Morgan Securities Inc. at (800) 245-8812.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future, including statements relating to the Tender Offer and any financing related thereto, growth, expected levels of expenditures and statements expressing general optimism about future operating results, are forward-looking statements. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements and those presented elsewhere by our management from time to time are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, but are not limited to, the satisfaction of conditions to the Offer, the ability to obtain financing on terms satisfactory to GeoEye and resulting in the receipt by GeoEye of proceeds in an amount sufficient finance the Offer, and those risks and uncertainties described in "Risk factors" included in our Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2008, which we filed with the Securities and Exchange Commission ("SEC") on April 2, 2009, and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 and June 30, 2009, which we filed with the SEC on May 12, 2009 and Aug. 10, 2009, respectively. A copy of all SEC filings may be obtained from the SEC's EDGAR web site, http://www.sec.gov/, or by contacting: William L. Warren, Senior Vice President, General Counsel and Secretary, at (703) 480-5672.

Photo: http://www.newscom.com/cgi-bin/prnh/20080625/LAW528LOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com GeoEye, Inc.

CONTACT: Investors, Randy Scherago, +1-703-480-7529,
scherago.randy@geoeye.com, or Media, Mark Brender, +1-703-629-5368,
brender.mark@geoeye.com, both of GeoEye, Inc.

Web Site: http://www.geoeye.com/

Jingwei International Changes the Independent Auditor to BDO

SHENZHEN, China, Sept. 11 /PRNewswire-FirstCall/ -- Jingwei International Limited (OTC Bulletin Board: JNGW -News; "Jingwei"), one of the leading providers in data mining and software services in China, today announced that Jingwei has engaged Bernstein & Pinchuk LLP, an independent member of the BDO Seidman Alliance, as its independent registered public accounting firm for the year ending December 31, 2009. Morison Cogen LLP had previously acted as its principal independent accountant, which engagement was discontinued effective as of September 2, 2009.

About Jingwei International

Jingwei International Limited ("Jingwei") is a leading provider of data mining and customer relationship marketing services in the fast growing Chinese market. Powered by advanced data mining technology and a proprietary database of over 300 million Chinese consumers, Jingwei enables leading Chinese companies as well as international brands to reach their target audiences. The Company's services include market segmentation, customer trend, revenue analysis and direct marketing. Jingwei is evolving into an integrated marketing service provider with targeted campaigns via multi media channels including: interactive mobile, telemarketing, direct mail and new media.

For more information, please visit the Company's web site: http://www.jingweicom.com/ .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the global financial crisis, effects of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. For more information, please contact:

Jingwei International Investment (Hong Kong) Limited

CONTACT: Regis Kwong, 86-755 86319436, regis@jingweicom.com, or
vanessa@jingweicom.com

Web Site: http://www.jingweicom.com/

Dey Issues Advisory

NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. , today issued an advisory regarding the theft of two different types of its respiratory medications, Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The lots were on a tractor-trailer that was stolen in the state of Florida.

The NDC numbers for the Ipratropium product are 49502-685-31 (lot number F09089) and 49502-685-62 (lot numbers C09119 and C09120). All packages contain 2.5 ml vials and display the brand name "DEY."

The NDC numbers for the Albuterol product are 49502-697-29 (lot number 9G04) and 49502-697-61 (lot numbers 9FD8, 9FD9 and 9FE1). All packages contain 3.0 ml vials and display the brand name "DEY."

In the weeks prior to the truck theft, some portion of each lot had been sold by Dey to its customers and successfully entered the legitimate pharmaceutical supply chain. Because the stolen product may have been stored or handled improperly, Dey is requesting that any and all product with the affected lot numbers be isolated and not be dispensed, sold or used. Dey has alerted its distributors and customers.

Anyone who has information about this incident, has received suspicious or unsolicited offers for the products in question or received product from these lots is encouraged to contact the U.S. Food and Drug Administration (FDA) Office of Criminal Investigations at 1.800.551.3989. Patient or customer inquiries for the company should be directed to Dey Customer Service at 1.800.527.4278.

Dey discourages patients from purchasing any medication sold outside of legitimate channels.

Dey L.P., a subsidiary of Mylan Inc. , is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies.

Mylan Inc.

CONTACT: Michael Laffin (Media), +1-724-514-1968, Dan Crookshank,
(Investors), +1-724-514-1813

Web Site: http://www.mylan.com/

EcoBlu Products, Inc. Corrects Release on Universal Forest Products

CARLSBAD, CA, Sept. 11 /PRNewswire-FirstCall/ -- EcoBlu Products, Inc. (OTCBB: ECOB) today announced that it would like to correct a misstatement in its press release of September 8, 2009. EcoBlu inaccurately reported that it had provided coating services for Universal Forest Products, Inc. (UFPI), when in fact it had provided services to a subsidiary of UFPI, Universal Forest Products Western Division, Inc. (UFPWD).

EcoBlu would like to make it clear that neither UFPI nor any of its affiliates and subsidiaries (collectively, "Universal") is in any way affiliated with EcoBlu. Universal and EcoBlu have no other relationship except that of vendor and customer. Universal supplies wood coated with Bluwood technology solely at the customer's request. Universal does not warrant or endorse the use of Bluwood technology and makes no claims as to its performance or efficacy. EcoBlu regrets any confusion the release may have caused and remains committed to providing our customers with the highest quality of wood treated lumber.

ABOUT ECOBLU PRODUCTS, INC.

EcoBlu Products, Inc. is a manufacturer of proprietary wood products coated with an eco-friendly chemistry that protects against mold, rot, decay, termites and value added fire. EcoBlu products protected by BLUWOOD(TM) technology is the ultimate in wood protection, preservation, and fire safety to building components constructed of wood; from joists, beams and paneling, to floors and ceilings. The Company is committed to the development, marketing and sales of environmentally-responsible building materials. EcoBlu products are ready to deliver the winning edge to builders and the environment with its sustainable green product line.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: The statements in this release relating to completion of the acquisition and the positive direction are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, contractual difficulties which may arise, the failure to obtain necessary approvals, the future market price of EcoBlu Products, Inc. common stock and the ability to obtain the necessary financing.

EcoBlu Products, Inc.

CONTACT: Company Contact: EcoBlu Products, Inc., Carlsbad, California,
92008, Phone: (909) 519-5470, Email: info@ecobluproducts.com, Web Site:
http://www.ecobluproducts.com/, Blog: http://blog.ecobluproducts.com/, Visit us on
YouTube at: http://www.youtube.com/ecobluproducts

DaVita Launches Nationwide Series of Kidney Awareness Run/WalksEvents Raise Funds and Educate Communities about the Silent Epidemic of Kidney Disease

DENVER, Sept. 11 /PRNewswire-FirstCall/ -- DaVita Inc. , a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), kicks off the DaVita Kidney Awareness Run/Walks(TM) - a 10-city series of 5K events raising funds and awareness of CKD across the nation -- on Sept. 13 at Stapleton Central Park in Denver.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

The Run/Walks will take place in Denver, Chicago, Cleveland, Cincinnati, St. Louis, Sacramento, Long Beach, Ft. Worth, Virginia Beach and Washington D.C.

A silent epidemic, CKD affects one in nine Americans, totaling around 26 million adults, with 90 percent unaware they are suffering from it. The chance that an American adult has CKD is almost as high as an American woman's risk of getting breast cancer. The Centers for Disease Control and Prevention recognize CKD as a major public health problem that reduces the quality and length of life. Beyond raising awareness around CKD, the free kidney screening and other services offered during the events aim to delay or prevent people from experiencing kidney failure and having to undergo dialysis.

"The statistics are staggering. As a team moving towards a common goal, we can get the word out about the importance of getting tested right now," said Barbara Lawson, President and CEO of The Kidney TRUST(TM), a 501(c)(3) non-profit organization working to prevent kidney disease through public education and awareness across the United States. All funds raised from this year's events will benefit The Kidney TRUST.

The DaVita Kidney Awareness Run/Walks will feature kidney health screenings at no cost, entertainment and games for the entire family, as well as a kidney health expo to promote awareness of CKD. Participants will be given the tools to educate their community about the importance of early testing.

For more information about registration for each event, please visit http://www.kidneyawarenesstime.org/.

DaVita and DaVita Kidney Awareness Run/Walks are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500 company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita has been recognized as the only FORTUNE 500 company on WorldBlu's annual List of Most Democratic Workplaces(TM). As of June 30, 2009, DaVita operated or provided administrative services at 1,493 outpatient dialysis facilities and acute units in approximately 700 hospitals located in 43 states and the District of Columbia, serving approximately 116,000 patients. As part of DaVita's commitment to building a healthy, caring community, DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. For more information about DaVita, its kidney education materials and its community programs, please visit http://www.davita.com/.

Photo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com DaVita Inc.

CONTACT: Kelsey Rood of DaVita Inc., +1-310-536-2404,
kelsey.rood@davita.com

Web Site: http://www.davita.com/
http://www.kidneyawarenesstime.org/

page 1    

News archive of November 2009
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30